Reversible transformation and de-differentiation of human cells derived from induced pluripotent stem cell teratomas

Human Cell

Volumn 29, Issue 1, 2016, Pages 1-9

  Kamada, Mizuna ^a   Mitsui, Youji ^a,b   Matsuo, Taira ^a   Takahashi, Tomoko ^a  

^a TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^b Foundation for Advancement of International Science   (Japan)

Author keywords

De differentiation; hiPSC therapy; Reprogramming; Transformation; Tumor risk

Indexed keywords

BETA GALACTOSIDASE; BMI1 PROTEIN; CALVASCULIN; CD31 ANTIGEN; CD34 ANTIGEN; GENOMIC DNA; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; ORGANIC CATION TRANSPORTER 3; PROTEIN; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P14; PROTEIN P16; PROTEIN P21; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; REX1 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; CULTURE MEDIUM; HOMEODOMAIN PROTEIN; NANOG PROTEIN, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CELL AGING; CELL DEATH; CELL DEDIFFERENTIATION; CELL GROWTH; CELL TRANSFORMATION; EMBRYONIC STEM CELL; FEMALE; FETUS; FETUS LUNG; GENETIC TRANSFECTION; HELA CELL LINE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LUNG FIBROBLAST; MOUSE; NONHUMAN; ONCOGENE; PLURIPOTENT STEM CELL; PRIMARY CULTURE; PRIORITY JOURNAL; TELOMERE SHORTENING; TERATOMA; ANIMAL; CULTURE MEDIUM; GENE EXPRESSION; GENETICS; INDUCED PLURIPOTENT STEM CELL; PATHOLOGY; STEM CELL TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; CELL DEATH; CELL DEDIFFERENTIATION; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CULTURE MEDIA; EMBRYONIC STEM CELLS; GENE EXPRESSION; HOMEODOMAIN PROTEINS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICE; NANOG HOMEOBOX PROTEIN; OCTAMER TRANSCRIPTION FACTOR-3; STEM CELL TRANSPLANTATION; TELOMERASE; TELOMERE SHORTENING; TERATOMA;

EID: 84953636470     PISSN: 09147470     EISSN: 17490774     Source Type: Journal    
DOI: 10.1007/s13577-015-0119-1     Document Type: Article

References (20)

1. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917–20.
2. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–72.
3. Fong CY, Gauthaman K, Bongso A. Teratomas from pluripotent stem cells: a clinical hurdle. J Cell Biochem. 2010;111:769–81.
4. Riken (2013) Pilot clinical study into iPS cell therapy for eye disease starts in Japan. Riken Press Release.
5. Miura K, Okada Y, Aoi T, Okada A, Takahashi K, Okita K, et al. Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol. 2009;27:743–5.
6. Nishimori M, Yakushiji H, Mori M, Miyamoto T, Yaguchi T, Ohno S, et al. Tumorigenesis in cells derived from induced pluripotent stem cells. Hum Cell. 2014;27:29–35.
7. Tano K, Yasuda S, Kuroda T, Saito H, Umezawa A, Sato Y. A novel in vitro method for detecting undifferentiated human pluripotent stem cells as impurities in cell therapy products using a highly efficient culture system. PLoS One. 2014;9:e110496.
8. Li W, Xiang AP. Safeguarding clinical translation of pluripotent stem cells with suicide genes. Organogenesis. 2013;9:34–9.
9. Kamada M, Mitsui Y, Kumazaki T, Kawahara Y, Matsuo T, Takahashi T. Tumorigenic risk of human induced pluripotent stem cell explants cultured on mouse SNL76/7 feeder cells. Biochem Biophys Res Commun. 2014;453:668–73.
10. Kumazaki T, Takahashi T, Matsuo T, Kamada M, Mitsui Y. Re-emergence of undifferentiated cells from transplants of human induced pluripotent stem cells as a possible risk factor of tumourigenesis. Cell Biol Int Rep. 2014;21:17–24.
11. Kumazaki T, Sasaki M, Nishiyama M, Teranishi Y, Sumida H, Eboshida A, et al. Life span shortening of normal fibroblasts by overexpression of BCL-2: a result of potent increase in cell death. Exp Cell Res. 2003;285:299–308.
12. Kamada M, Kumazaki T, Matsuo T, Mitsui Y, Takahashi T. Establishment of ultra long-lived cell lines by transfection of TERT into normal human fibroblast TIG-1 and their characterization. Cell Biol Int. 2012;36:519–27.
13. Kumazaki T, Kurata S, Matsuo T, Mitsui Y, Takahashi T. Establishment of human induced pluripotent stem cell lines from normal fibroblast TIG-1. Hum Cell. 2011;24:96–103.
14. Mori S, Chang JT, Andrechek ER, Matsumura N, Baba T, Yao G, et al. Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene. 2009;28:2796–805.
15. Ohashi M, Aizawa S, Ooka H, Ohsawa T, Kaji K, Kondo H, et al. A new human diploid cell strain, TIG-1, for the research on cellular aging. Exp Gerontol. 1980;15:121–33.
16. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science. 2008;322:949–53.
17. Kim D, Kim CH, Moon JI, Chung YG, Chang MY, Han BS, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell. 2009;4:472–6.
18. Fu W, Wang SJ, Zhou GD, Liu W, Cao Y, Zhang WJ. Residual undifferentiated cells during differentiation of induced pluripotent stem cells in vitro and in vivo. Stem Cells Dev. 2012;21:521–9.
19. Papp B, Plath K. Reprogramming to pluripotency: stepwise resetting of the epigenetic landscape. Cell Res. 2011;21:486–501.
20. Yamasaki S, Taguchi Y, Shimamoto A, Mukasa H, Tahara H, Okamoto T. Generation of human induced pluripotent stem (Ips) cells in serum- and feeder-free defined culture and TGF-Beta1 regulation of pluripotency. PLoS One. 2014;9:e87151.